127 related articles for article (PubMed ID: 9922713)
1. [Antioxidative effects of fluvastatin, and its major metabolites].
Nakashima A; Ohtawa M; Masuda N; Morikawa H; Bando T
Yakugaku Zasshi; 1999 Jan; 119(1):93-9. PubMed ID: 9922713
[TBL] [Abstract][Full Text] [Related]
2. [Antioxidative effects of fluvastatin, and its major metabolites [II]].
Nakashima A; Ohtawa M; Masuda N; Morikawa H; Iwasaki K
Yakugaku Zasshi; 2001 Jan; 121(1):113-6. PubMed ID: 11201159
[TBL] [Abstract][Full Text] [Related]
3. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes.
Yamamoto A; Hoshi K; Ichihara K
Eur J Pharmacol; 1998 Nov; 361(1):143-9. PubMed ID: 9851551
[TBL] [Abstract][Full Text] [Related]
4. Antioxidative effect of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes.
Yamamoto A; Ichihara K; Hoshi K
J Pharm Pharmacol; 2001 Feb; 53(2):227-32. PubMed ID: 11273020
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of fluvastain and its metabolites on the formation of several reactive oxygen species.
Nakashima A; Ohtawa M; Iwasaki K; Wada M; Kuroda N; Nakashima K
Life Sci; 2001 Aug; 69(12):1381-9. PubMed ID: 11531162
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of fluvastatin, an HMG-CoA reductase inhibitor, on the formation of 8-oxo-2'-deoxyguanosine in the nuclear DNA of hamster pancreas after a single administration of N-nitrosobis(2-oxopropyl)amine.
Kaneko T; Tahara S; Takabayashi F
Biol Pharm Bull; 2003 Sep; 26(9):1245-8. PubMed ID: 12951466
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein.
Suzumura K; Tanaka K; Yasuhara M; Narita H
Biol Pharm Bull; 2000 Jul; 23(7):873-8. PubMed ID: 10919369
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
Suzumura K; Yasuhara M; Tanaka K; Suzuki T
Biochem Pharmacol; 1999 Mar; 57(6):697-703. PubMed ID: 10037456
[TBL] [Abstract][Full Text] [Related]
10. Antioxidative potential of fluvastatin via the inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.
Bandoh T; Sato EF; Mitani H; Nakashima A; Hoshi K; Inoue M
Biol Pharm Bull; 2003 Jun; 26(6):818-22. PubMed ID: 12808293
[TBL] [Abstract][Full Text] [Related]
11. Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice.
Imaeda A; Kaneko T; Aoki T; Kondo Y; Nakamura N; Nagase H; Yoshikawa T
Food Chem Toxicol; 2002 Oct; 40(10):1415-22. PubMed ID: 12387303
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation.
Suzumura K; Odawara A; Yasuhara M; Tanaka K; Narita H; Suzuki T
Biol Pharm Bull; 1999 Sep; 22(9):971-4. PubMed ID: 10513623
[TBL] [Abstract][Full Text] [Related]
14. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
[TBL] [Abstract][Full Text] [Related]
15. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
[TBL] [Abstract][Full Text] [Related]
16. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
Aoki S; Ikeda K; Yamamura M; Kojo S
Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
[TBL] [Abstract][Full Text] [Related]
18. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
Yasunari K; Maeda K; Minami M; Yoshikawa J
Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits.
Akira K; Amano M; Okajima F; Hashimoto T; Oikawa S
Biol Pharm Bull; 2006 Jan; 29(1):75-81. PubMed ID: 16394514
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
